Lupin Limited has informed the Exchange regarding a press release dated August 20, 2025, titled "Lupin Launches Bosentan Tablets for Oral Suspension in the United Stateswith 180-Day Exclusivity".
Press Release Aug 20 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Press Release Aug 12 2025
- Press Release Aug 11 2025
- Press Release Aug 05 2025
- Press Release Jul 24 2025
- Press Release Jul 17 2025
Later from Lupin
- Press Release Sep 03 2025
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
- Press Release Sep 17 2025
- Press Release Sep 24 2025
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin